New York Times Story Brings New Questions Surrounding Drug’s FDA Approval For Xarelto Lawsuit Plaintiffs

April 05, 2016 – – BloodThinnerHelp.com reports on recent revelations made by the New York Times through an article discussing two major pharmaceutical manufacturers who produce new-generation, anticoagulant drug Xarelto. The allegations, which have spurred controversy from the general public as well as current plaintiffs involved in Xarelto related lawsuits, allege that Bayer Healthcare and Johnson & Johnson subdivision Janssen Pharmaceuticals may have purposefully misled the editors of an incredibly prestigious medical journal by omitting important data surrounding Xarelto.

Throughout the country, over 3,400 lawsuits have been filed concerning Xarelto, and all plaintiffs share strikingly similar allegations relating to the drug putting patients at increased risk for the development of dangerous and sudden bleeding events. Filed lawsuits have been consolidated to form two main groupings: 2,800 federally-filed cases have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL No. 2592 in a single Court in Eastern Louisiana, while more than 620 other Xarelto lawsuits have been consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania to form a mass tort program.

With the release of this new information, plaintiffs are now concerned about more than just the blood thinner’s potentially dangerous or fatal side effects. After a letter was published in The New England Journal of Medicine, authored mostly by researchers at Duke University, and brought back into the light recently, plaintiffs are seeing new controversies. Plaintiffs now realize that this letter may have intentionally omitted deeply important laboratory data from tests conducted on the drug, which could have led to a premature FDA-approval. Plaintiffs claim that through remaining silent about this critical problem, the companies have also intentionally misled consumers and the general public. They indicate that after the data was published, the companies even used this same data to provide information regarding the drug to regulators in both the U.S. and Europe.

The recent New York Times article investigates this possibility and insinuates that manufacturers Bayer and Johnson & Johnson, in addition to others who assisted with conducting Xarelto clinical trials at Duke University, have potentially lied by omission to the editors of the New England Journal of Medicine. In addition, these individuals may have pushed FDA-approval of the anticoagulant drug sooner, by omitting important information for the agency’s consideration.

As involved plaintiffs await the results of further investigations into these controversies, Attorney Joseph Osborne is working to ensure that other patients who have used Xarelto and who feel they have been negatively affected by the drug will be provided with the opportunity to investigate their legal rights fully. Affected patients could be entitled to significant compensation gained through legal action. To better assist those interested, Attorney Osborne is offering complimentary legal consultations concerning Xarelto for qualifying individuals at this time.

To request further Xarelto lawsuit information, or to ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60009089